CEO: Expects to deliver positive Rev growth and double digit EPS growth in 2019 - conf call comments
- To absorb roughly $2B of erosion related to biosimilar competition
- Humira in U.S. to continue to generate 'strong Rev', driving roughly $1B of growth in 2019
- Humira biosimilar competition is now upon us